pharmaphorum| News & views on pharma and biotech’s evolving future

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Oncology

pharmaphorum podcast Episode 286, Kate Estep, Flatiron Health

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

Patients

Five diseases that changed rare disease R&D

News

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News

Neurosterix' $105m round leads the week's biotech financings

Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.

Featured Content

Oncology

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

Patients

Rare diseases are not a niche, but Europe’s opportunity to c...

Rare diseases are individually uncommon, but collectively affect up to 36 million people in the European Union.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Oncology

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Sales & Marketing

Sponsored

Are Insights leaders seeing real commercial value from AI ad...

Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.

Newsletters and Deep Dive
digital magazine

Latest News

News

Windward Bio catches $175m from its IPO

Swiss biotech Windward Bio has raised $175m in its Nasdaq IPO as it prepares to take on some heavyweight rivals with its long-acting TSLP inhibitor.

News

Neurosterix' $105m round leads the week's biotech financings

Neurosterix raises $105m for its schizophrenia candidate, as Delix, VectorY, and Eli Radiopharma also add to their cash reserves.

News

Rapid DEA review clears way for Takeda's narcolepsy launch

Takeda has started to roll out its new narcolepsy therapy in the US, with competitive pricing to Jazz Pharma's current market leader Xywav.

News

Microsoft outage disrupting healthcare; reports

There are reports of disruption to health services around the world as a result of the Microsoft outage, with the UK's NHS said to be badly affected.

Views & Analysis

Oncology

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

R&D

Life sciences real estate: Beyond labs

Growth in biotechnology, pharmaceutical R&D, and advanced therapies is driving demand for specialist laboratory space.

R&D

Inspection readiness is now a commercial question

Manufacturers of advanced therapies are discovering that a digital quality system does more than satisfy inspectors.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Deep Dive

Patients

Deep Dive Rare Disease 2026

Patients

Five diseases that changed rare disease R&D

Patients

Rare diseases are not a niche, but Europe’s opportunity to c...

Rare diseases are individually uncommon, but collectively affect up to 36 million people in the European Union.

Patients

The UK Rare Diseases Framework: Ensuring healthy equity for ...

White Papers & Webinar

Sales & Marketing

Sponsored

Securing your ROI: Turning post-acquisition integration into...

Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.

Sales & Marketing

Sponsored

Are Insights leaders seeing real commercial value from AI ad...

Day One Strategy’s second annual AI in Pharma State of Play report addresses the challenges Pharma Insights teams are facing as AI adoption continues.

Digital

IQVIA Technologies White Paper Cover Image

Sponsored

From Automation to Decision Intelligence: The Next Operating...

In this free white paper, IQVIA experts and thought leaders explore the real challenges and bottlenecks in pharmacovigilance today.

Digital

The State of AI in Clinical Trials White Paper

Sponsored

From Pilot to Practice: Insights into AI Adoption, Impact, a...

Read Medidata’s 2nd annual survey, 'The State of AI in Clinical Trials. From Pilot to Practice: Insights into AI Adoption, Impact, and Expectations'.

Podcasts & Video

Oncology

Closing the global evidence gap in oncology, with Flatiron H...

Kate Estep discusses Flatiron’s AI-powered oncology intelligence platform, Telescope, and how AI tools are changing research decisions.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.

Oncology